17th July 2018
- 0 comments
Univercells SA and Global Health Investment Fund have closed a €16 million ($18.8M) Series B equity financing. Investment proceeds will support the continued development of Univercells’ game-changing biomanufacturing technology, which has the potential to dramatically reduce the capital expenditure, physical footprint and operating costs required to produce a variety of complex biologics.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.